Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
20.70
-0.01 (-0.05%)
May 2, 2025, 4:00 PM EDT - Market closed
Celldex Therapeutics Analyst Ratings
Total Analysts
9
Consensus Rating
Buy
Price Target
$55.50
Upside
+168.12%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $64 | Strong Buy | Initiates | $64 | +209.18% | Apr 28, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $46 | Buy | Initiates | $46 | +122.22% | Mar 20, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $42 → $36 | Hold | Maintains | $42 → $36 | +73.91% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +286.47% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +286.47% | Feb 28, 2025 |
| UBS | UBS | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | +112.56% | Feb 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $67 | Buy | Reiterates | $67 | +223.67% | Jan 29, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $67 | Buy | Reiterates | $67 | +223.67% | Jan 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +286.47% | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +286.47% | Dec 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +286.47% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +286.47% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +286.47% | Oct 28, 2024 |
| Citigroup | Citigroup | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +238.16% | Oct 7, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $45 | Hold | Initiates | $45 | +117.39% | Sep 30, 2024 |
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 27, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.